Leptospirosis Is Estimated To Witness High Growth Owing To Rising Incidences Of Disease
Leptospirosis Market |
The global Leptospirosis Market
is estimated to be valued at US$ 496.8
Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted
in a new report published by Coherent Market Insights.
Market Overview:
Leptospirosis is a zoonotic
disease caused by pathogenic Leptospira interrogans bacteria. The disease
affects both humans and animals through contact with urine of infected animals.
The market offers vaccines, antibiotics and diagnostic tests to treat and
prevent the disease. Effective vaccines are playing a key role in curbing the
spread of the bacteria.
Market key trends:
One of the key trends fueling the
market growth is rising adoption of vaccination programs globally, especially
in regions with high disease prevalence. Growing awareness about the disease
and availability of effective vaccines is encouraging governments as well as
private organizations to invest in vaccination of at-risk population and
livestock. Furthermore, initiatives by international organizations such as WHO
to control and eliminate leptospirosis through global action plan are also
boosting the market size. Lastly, improved diagnostics and continuous pipeline
of innovative products are expected to drive further growth during the forecast
period.
Segment Analysis
Leptospirosis market is segmented
into drugs and diagnostics. Among these, drugs segment accounted for the
largest market share in 2022 owing to rising awareness regarding leptospirosis
treatment and increasing research and development activities for leptospirosis
therapeutics. Diagnostics segment is expected to witness lucrative growth over
the forecast period due to growing number of diagnostic tests available for
accurate detection of leptospirosis.
Key Takeaways
The Global
Leptospirosis Market Size is expected to witness high growth,
exhibiting CAGR of 5.8% over the forecast period, 2023 to 2030, due to
increasing incidence of leptospirosis worldwide.
Regional analysis
North America dominated the
global Leptospirosis market in 2022 and is expected to remain dominant during
the forecast period. This is attributed to favorable government initiatives
towards spreading awareness about leptospirosis and presence of major players
in the region. Asia Pacific is anticipated to witness lucrative growth over the
coming years owing to rapid development of healthcare infrastructure and
increasing prevalence of leptospirosis cases in the region.
Key players
Key players operating in the
Leptospirosis market are USAntibiotics, Dr. Reddyâ€TMs Laboratories Ltd.,
Century Pharmaceuticals Ltd., Mayne Pharma Group Limited, Sun Pharmaceutical
Industries, Inc., Ralington Pharma, F. Hoffmann-La Roche Ltd, Pfizer Inc.,
Sandoz International GmbH, ISKON REMEDIES & GMT, Haustus Biotech Pvt. Ltd.,
and Aden Healthcare.
Read more
https://www.dailyprbulletin.com/leptospirosis-market-size-share-growth-outlook-2023
Comments
Post a Comment